• Archaic technology contributes to dismal recurrence rate in bladder cancer
• Imagin Medical revolutionizes the way surgeons can visualize cancer to better identify, and remove during surgery
• There is potential to extend this technology to virtually other endoscopic procedures

The battle against cancer is too often set back by crushing blows of recurrence. The disease is insidious. If every single malignant cell of a tumor is not completely removed, it can rebound and attack again. Nowhere is this dismal recurrence more prevalent than in bladder cancer. Caught early, bladder cancer stands a better chance of being successfully treated through surgery and therapeutics. However, bladder cancer has the highest recurrence rate of all cancers. 50% of bladder cancers recur, attacking anew from a just few cells that were missed during surgery. Surgeons do the best they can, but with outdated technology they can’t clearly visualize inside the bladder, clearly identify and then remove potentially malignant cells. This dilemma is about to be rectified with a breakthrough new technology that, will gives surgeons, not only the ability to clearly see inside the bladder, but also more easily identify and surgically remove all the cancer

With bladder cancer as its first target, surgical imaging company Imagin Medical (CSE: IME) (OTCQB: IMEXF) intends to change the dismal outcomes of bladder cancer recurrence with its i/Blue Imaging(TM) System. The company’s patented, ultrasensitive imaging technology aims to revolutionize the archaic techniques currently used in treating bladder cancer and extend the technology to multiple other surgical procedures.

Conventional diagnostic procedures for visualizing bladder cancer during surgery allow surgeons to see inside the body with a thin, lighted, flexible tube which uses white light to illuminate the bladder. White light images show a full picture of the bladder but do not effectively highlight cancerous cells which can be left behind to attack again. A recent advancement uses blue-filtered white light to better detect tumors and cancerous cells not seen with white light. However, surgeons cannot use blue light images to operate. Blue cystoscope images aren’t in real time and the position in the bladder can be confusing, requiring the surgeon to manually switchback and forth from white to blue light images These technologies remain lacking and recurrence remains at high levels. 600,000 people live in fear that their cancer will return, unfortunately about half of them will have their worst fears realized.

Imagin Medical’s i/Blue Imaging System rectifies the limitations of white and blue light cystoscopies. Combining both the white and blue light with an FDA approved imaging agent, the i/Blue System displays side-by-side images in real-time, eliminating the need to switch back and forth between the two images. Using the i/Blue System, surgeons can now see the full landscape of the bladder and identify malignant cells in a single, unified process. This technological advancement is expected to drive down the dismal recurrence of bladder cancers and deliver hope to the tens of thousands that suffer with the disease.

Imagin Medical’s unique i/Blue Imaging System can attach to virtually any endoscope model currently in use which creates a plug and play system adaptable to almost any clinical setting which opens vast new markets for the company’s technology. The FDA approval process is underway, and the company’s intellectual property is well-protected.

Imagin Medical has reimagined technology to create better outcomes for cancer patients, and as the technology gains traction it may well become the new standard of care for bladder cancer and other endoscopic procedures.

For more information, visit the company’s website at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

• Holding company Clean Power Capital Corp.’s investee PowerTap, a hydrogen fueling innovator, has teamed with carbon energy credits expert Carbonomics to develop and maximize the company’s ability to use clean energy credits
• PowerTap is driven to establish a “hydrogen highway” for environmentally conscious motorists looking for an effective alternative fuel
• Clean Power Capital is a majority investor in PowerTap — a key part of Clean Power’s focus on building up health and renewable energy enterprises
• PowerTap’s next-generation hydrogen stations are also capable of generating electricity to help them continue to pump fuel during a power outage or even potentially power the entire gas stop operation where the fuel stations are located

Holding company Clean Power Capital (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) advanced its mission of helping health and renewable energy enterprises achieve their growth potential when it became a majority investor in California’s PowerTap Hydrogen Fueling Corp last fall. PowerTap has proven to be a formidable innovator in the clean power industry through its recent agreements with the Andretti Group for fuel station location, marketing and leadership (https://ibn.fm/lF640). Now PowerTap is maximizing its ability to navigate the regulatory hurdles for obtaining certification and emission reduction credits in the United States and international markets by teaming up with Carbonomics, and expert in the process of monetizing carbon credits. “Carbon credits are a key part of every clean energy company’s strategy, and we are pleased to partner with Carbonomics to leverage their expertise and experience to maximize carbon credit revenues,” stated PowerTap CEO Raghu Kilambi (https://ibn.fm/UUvfG). “Leading clean energy companies like Tesla have used emission-reduction credit revenues (https://ibn.fm/K8cBV) to accelerate their growth and cash flow.” PowerTap is preparing to install its 1,250-kilogram hydrogen production and dispensing stations at some of the Andretti Group’s more than 100 retail chain stores, which are focused on fuel, convenience and food operations through facilities under the Chevron, Texaco, Shell, 76, Circle K, Pacific Pride and CFN and other brands. The stations are noteworthy not only for their role in helping to build up a “hydrogen highway” throughout California and eventually into other parts of the country, but also because they are capable of generating electricity. “While much less electricity is needed to produce blue hydrogen vs green hydrogen (https://ibn.fm/39Un2), PowerTap recognized that electricity shortages may affect the operation of its fueling stations,” the company stated in a recent news release acknowledging the power outages in Texas brought on by unusual freezing weather (https://ibn.fm/D9Bd3). “To address this potential issue, PowerTap’s 3rd Generation Onsite Hydrogen fueling unit will have an industrial hydrogen fuel cell that can be used to turn excess hydrogen into electricity that can be used in various capacities including powering further hydrogen production or the rest of the gas/truck stop operations.” PowerTap is a key part of Clean Power Capital’s investment portfolio. Clean Power’s investment mandate is focused on high return investment opportunities, the ability to achieve a reasonable rate of capital appreciation and to seek liquidity in its investments. For more information, visit the company’s website at www.CleanPower.Capital. NOTE TO INVESTORS: The latest news and updates relating to MOTNF are available in the company’s newsroom at https://ibn.fm/MOTNF

• PlantX Life welcomes new brand ambassadors Venus Williams and Alicia Silverstone
• Plant-based lifestyle allowed Williams to “continue her dreams” as a world-renowned tennis player
• Silverstone chose plant-based two decades ago, calling it “just a healthier way to be”

PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) has announced world-renowned tennis player Venus Williams and well-known actress Alicia Silverstone as brand ambassadors for the company — a company that Williams noted is “long overdue.” “I can’t tell you how excited I am to be involved, an ambassador, a cheerleader, a stakeholder, and all the above, in PlantX,” said Williams following the announcement, which was made during the company’s annual general meeting (https://ibn.fm/lVSOG). “It’s the first market of its kind, and it’s long overdue.” A former number 1-ranked tennis player with four Olympic gold medals and seven Grand Slam singles titles to her name, Williams first became involved in a plant-based lifestyle 10 years ago when she was diagnosed with an autoimmune disease that threatened to derail her tennis career. At the suggestion of her sister Serena, also a world champion tennis player, Williams committed to a three-week, all-raw vegan program and saw immediate results. “That was my introduction,” she said. “Not only did I learn a lot about food but the food system, and how it fills your body and how we have strayed so far away from where we started as humans and to where we are right now.” Williams noted that a plant-based lifestyle has “become my passion and my hobby, and it’s been able to help me not only get back on tour but also to live a much better quality of life, because when you have a chronic illness, your quality of life goes down. To be able to live a much better quality of life was obviously the first step, and then to be able to continue to live my dreams was the second step.” Silverstone noted similar health benefits when she adopted her vegan lifestyle 20 years ago before many people were even familiar with it, she said, speaking about her enthusiasm for PlantX and her role as a brand ambassador for the Company. Although her primary motivation for choosing a plant-based diet was because she loved animals, she suffered from allergies and wanted to lose weight. “I took on this new way of eating, and I ditched all of that,” she said. “My asthma inhaler went away, my allergy shots went away, my body started to slim down, and this was all by accident. I just did it because I didn’t want to be mean to my dog anymore. . . I made the change but all these amazing health things began to happen. As I did research and started to look at all these studies, it just shows [plant-based] is just a healthier way to be.” Since her decision, Silverstone has become an outspoken advocate for health and wellness, with a particular interest in and support for the plant-based lifestyle. Silverstone and Williams have high praise for PlantX Life, a company that is pioneering its path in the plant-based space. As the digital face of the plant-based community, PlantX’s platform is the one-stop shop for everything plant-based. With its fast-growing category verticals, the Company offers customers across North America more than 10,000 plant-based products. In addition to offering meal and indoor plant deliveries, PlantX currently has plans to expand its product lines to include cosmetics, clothing and its own water brand. In addition, the Company uses its digital platform to build a community of like-minded consumers and to provide education. Its successful enterprise is being built and fortified through partnerships with top nutritionists, chefs and brands. For example, the company offers 20 unique pre-made meals designed by top chefs and nutritionists. These healthy meals are offered at extremely competitive prices with fast shipping and round-the-clock convenience. The Company’s commitment to customer service is the driving force behind its e-commerce platform, with innovative thinking driving its operation; the PlantX team is constantly envisioning new ways to collaborate with local restaurateurs and entrepreneurs to bring PlantX to the world. PlantX is committed to eliminating the barriers to entry for anyone interested in living a plant-based lifestyle and thriving in a longer, healthier and happier life. For more information, visit www.PlantX.com, www.PlantX.ca and www.Investor.PlantX.com and view the PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• Testing is more important than ever, medical experts claim, urging government to speed up widespread testing
• Tens of millions of rapid, at-home tests may be needed every day
• UME offers rapid testing kits to help end the pandemic, ready to seize the opportunity

The U.S. government has announced plans to roll out more than 60 million home test kits to stop the COVID-19 virus from spreading (https://ibn.fm/O89KJ). United Medical Equipment Business Solutions Network (“UME”), a company offering a comprehensive line of COVID-19 products including rapid testing kits, stands ready to capitalize on the growing push for widespread testing and help slow the global pandemic.

Health experts agree with the new administration’s commitment to widespread rapid testing, but some fear that officials do not respond quickly enough. “Testing is actually more important now than it was eight months ago because of the high contagiousness rate of these new variants,” says Mara Aspinall, a professor of health practice at Arizona State University, said in a recent interview for NPR. “It is critical to stop these new strains right in their tracks. And the only way to do that is to test.”

Identifying infected people through country-wide rapid testing could be vital for curbing the virus and preventing new variants from emerging. The country reportedly needs tens of millions of tests every day to avoid another surge, while it buys time to get enough people vaccinated. “The virus still has an impressive grip on us. We need to be scaling these [tests] up today.”, said Dr. Michael Mina, an infectious disease epidemiologist at the Harvard T.H. Chan School of Public Health, in the article. Dr. Mina urges the Food and Drug Administration to approve more simple, rapid, inexpensive tests. They can be made quickly, thus enabling frequent testing of people at their homes.

Widespread rapid testing could jumpstart testing rates that have been stagnating at 1.6 million a day. At-home tests could make up for shortages in supplies, and the often-long wait times that come with the gold-standard PCR testing.

Other countries have already implemented rapid at-home testing. For example, amid the surge in COVID-19 cases in early 2021, the UK government announced it would roll out millions of cheap, rapid virus tests — a potential game changer in the fight against the virus (https://ibn.fm/ngMgh).

As a company committed to providing essential services during the epidemic, UME offers a comprehensive COVID-19 monitoring toolset designed with the assistance of medical experts. It includes data-driven COVID-19 testing of people with or without symptoms and could be useful for testing those in close contact with someone who has the virus. The Company appears ideally positioned to benefit from the pent-up demand for the rapid test as the push for widespread testing continues to grow.

For more information, visit the company’s website at www.UnitedMedSolutions.com.

NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment are available in the company’s newsroom at  https://ibn.fm/UnitedMed

• Digital subscription platforms have become increasingly popular because they bridge the gap created by closing venues because of the pandemic
• Billboard Bulletin covers the future of live streaming, record labels, and the music industry – citing the experience of Patreon CEO Jack Conte, who has seen exponential growth in the last year
• Friendable’s application Fan Pass has seen 100% growth in live streaming events and artist performances in 2021
• Digital subscription platforms are driven by the superfans and Generation Z social media users and influencers

Although many digital subscription platforms were in existence prior to the monumental impact the pandemic made on the industry in 2020, many did not see unprecedented growth in subscription rates until then. Releasing a digital subscription for fans in 2020, mobile technology and marketing company Friendable (OTC: FDBL) has seen exponential and consistent growth since launching its platform for fans to gain exclusive access to the artists they love. A recent Billboard Bulletin article goes over the future of live streaming, record labels, and the music industry. Available only to paid subscribers at https://ibn.fm/O4JMW, the article quotes Patreon CEO Jack Conte as saying that “the last year has shown artists that subscription platforms are another revenue stream that they can develop in addition to touring and used to offer exclusive content tide to their live shows.” Patreon was founded in 2013 and pioneered the subscription membership platform industry. The company is popular due to its creator-friendly revenue splits. Friendable has already seen a 100% growth in live stream events and artist performances in 2021. In a press release, Friendable’s CEO Robert A. Rositano Jr. said that metrics mean everything – whether they show an increase or a decrease, and that the metrics the company sees guide the teams on the Fan Pass journey (https://ibn.fm/lxN7h). “I am happy to report that Fan Pass is being embraced on all fronts in more ways than I could have imagined,” Rositano Jr. added. “An active community breeds additional activity, content growth and fan engagement, which all feeds the subscription revenue model, artist ticket/event sales and overall merchandise exposure for additional e-commerce revenue. In addition, we believe the convergence of all these advances together will bring Fan Pass closer to attracting its first sponsor and open the door to additional revenue opportunities that are now becoming even clearer.” The Fan Pass platform is a mobile technology and marketing platform designed to help artists engage with their fans worldwide and earn revenue while doing so. Fan Pass brings an “all-access” VIP experience that includes:

• Live performances and online concerts
• Backstage meet & greets before and after the pay-per-view events
• Livestreamed content of studio sessions
• Behind-the-scenes footage of music videos and photoshoots
• Special interviews and one-on-one video
• Streams that highlight the daily lives of the artist

The subscription to the platform starts at $3.99 and provides single-purchase pay-per-view exclusive content like concerts for fans. With the closure of most live music venues worldwide, Fan Pass was designed to help bridge the gap left by the pandemic by enabling connection and engagement between artists and fans. The Billboard Bulletin article also points out that digital subscription platforms that fill the void left by the pandemic are coming off of 12 months of unprecedented subscriber growth due to the high number of artists that joined the platforms. The subscriptions are the equivalent of real-time fan clubs for members of Generation Z who have grown up with micropayments and maintaining multiple subscriptions for media and entertainment. The fan clubs of today are more engaged than they were 20+ years ago when you sent a letter and hoped for an autograph in return. Fans expect exclusive material, VIP tickets, rare merchandise items, and virtual concerts, the article underlines. The reach that subscription platforms have is partially due to the rise of social media and influencers. These have bred the perfect environment to create superfans, which are more impactful thanks to social media use. Artists are inspired and motivated by the superfans because they are often more a part of the artist’s world than the artists themselves. Friendable and Fan Pass are leveraging their success on fans’ desire to gain instant access to the artists they love. Future artists will now cultivate their skills through entrepreneurial qualities, not rely on the traditional record companies to pave a path they can’t recoup from. Revenue streams are readily available through the digital subscription services providing labels and artists access to first-line data that can be used to provide real value and capture a piece of the media budget, the Billboard Bulletin article also notes. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• High Pressure Processing (“HPP”) has become a highly successful method to reduce pathogens and extend shelf-life in food and beverages while maintaining taste, nutrition, flavor, and texture
• The HPP food and beverage market was estimated at $15.5 billion in 2019
• PBI’s UST process combines benefits of HPP with high shear and controlled temperature to achieve effective anti-microbial effects and long-term preservation with reduced or no chemicals
• Academia-Industry partnership will give global food companies in Consortium an early look and first-hand use of UST, with a right to non-exclusively license UST for their own commercial use
• This revolutionary, transformative technology is not just applicable to the massive food and beverage markets, but to the pharmaceutical, nutraceutical, cosmetics, and agriculture markets
• The Consortium resulted from research initially sponsored by the USDA NIFA

Pressure BioSciences (OTCQB: PBIO) (“PBI”), a developer of innovative, pressure-based solutions for the worldwide life sciences and other industries, and the College of Food, Agricultural, and Environmental Sciences (“CFAES”) at The Ohio State University (“Ohio State”) announced a wide-ranging agreement for the implementation of PBI’s patented Ultra Shear Technology(TM) (“UST”) platform. PBI is developing three different models of the UST processing instrument, named the BaroShear: a small footprint benchtop model, a medium capacity floor model, and an industrial scale, continuous flow model for high capacity. All three models are designed to perform high shear processing of liquids under controlled temperatures and pressure conditions. They will be set up for demonstration and hands-on use in the world-renowned Ohio State food pilot plant (https://ibn.fm/BxEdd).

PBI is a leader in development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agriculture, and food/beverage industries. Together with Ohio State, whose CFAES is a globally recognized leader in the food sciences, PBI has formed a food industry consortium to advance the commercialization of its UST platform through the quality enhancement of beverages, condiments, sauces, and other liquid foods. Consortium members will have access to the UST technology in the Ohio State pilot plant and first rights to license all new UST applications developed through the Consortium.

The primary goals of the Consortium are:

• Develop and improve new commercial applications of UST
• Help address potential regulatory issues through scientific support
• Allow global food companies worldwide to experience UST product development and pre-commercialization efforts first-hand

Additionally, Consortium members will be rewarded with “first-look” opportunities to all new UST developments and first rights to non-exclusively license all new applications for commercial purposes.

According to Pressure BioSciences President and CEO Richard T. Schumacher, the Consortium will welcome a global group of preeminent leading food and beverage companies as members. “Each will contribute annually towards the Consortium’s operations, with funds supporting R&D at both PBI and Ohio State while participating as an advisory council to nominate, prioritize and direct UST applications development amongst the myriad opportunities that invite our attention,” he explained.

Food companies worldwide will have access to the Consortium, and members will help direct the scientific effort of OSU and PBI across prospective liquid food and beverage projects. The current topics of interest include:

• Spore inactivation and control of other pathogen and spoilage factors
• Enhancement of taste, smell, and other sensory qualities in liquid foods
• Formation of highly stable products that are suitable for ambient temperature storage, transportation, and distribution

Over the last two decades, high pressure processing (“HPP”) has established itself as a very successful clean-label (reduced or no chemical additives) approach for food safety and improved product life, according to PBI Senior Vice President of Engineering Dr. Edmund Y. Ting. As a result, the high pressure processing (“HPP”) food market reached $15.5 billion in 2019 and is expected to increase substantially through 2025 (https://ibn.fm/sY5RY). The HPP market makes some (not all) food safer, more stable, more nutritious, better tasting, and with fewer chemicals (clean label).

According to Dr. Edmund Ting, Sr. VP of Engineering at PBI and a pioneer in the development of HPP, “HPP has proven to be very effective in reducing food-borne pathogens and extending shelf-life in pre-packaged foods (e.g., juices and ready-to-eat meats), thus eliminating the need for chemical additives. However, because it is only a pasteurization process, and does not render food “commercially sterile”, HPP-processed food must be shipped, stored, and maintained under refrigeration throughout the entire chain of distribution and retail sale. We believe that Ultra Shear Technology will provide economical solutions to these problems, and will offer an additional, clean label processing choice to both consumers and the food industry around the world.”

The potential of UST is not just limited to food and beverages. Through this revolutionary platform, vitamins and cannabinoids could be infused into beverages, remaining in them without precipitating out, as is often seen today. Gels, creams, ointments, and other lotions could penetrate the skin faster and more completely, bringing the active ingredient to where it needs to be faster and with higher bioavailability. Vaccines and therapeutics could be enhanced and improved. The applications and benefits are seemingly endless.

PBI and Ohio State gratefully acknowledge the initial research support by the USDA NIFA, which resulted in the Consortium.

For more information, visit the company’s website at www.PressureBioSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

• Berubicin is CNS Pharmaceuticals’ lead product candidate for treatment of Glioblastoma Multiforme, and has the potential to be the first anthracycline to cross the blood-brain barrier based on limited results from a Phase 1 trial
• The market for GBM treatment is estimated to reach $3.3 billion in 2024, growing at a CAGR of 17.4%
• CNS, in collaboration with sublicensee partner WPD Pharmaceuticals, is currently planning three Berubicin clinical trials, all to start within the year – two Phase II adult trials and a pediatric Phase I trial

Glioblastoma Multiforme (“GBM”) is one of the most aggressive forms of brain cancer in the adult population and is currently considered incurable, with a significant recurrence rate in most patients. Even with gross total resection of the GBM tumor, there is always a microscopic amount of disease that gets left behind. A gross total resection of GBM is defined as removing at least 98% or more of the tumor that has been contrast-enhanced and visible on an MRI.

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company that is currently specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, hopes to address this issue and improve the lives of GBM patients while also lowering recurrence risks with its lead drug candidate, Berubicin.

Developed by Dr. Waldemar Priebe, Ph.D., the Chairman of the Scientific Advisory Board for CNS Pharmaceuticals, and a Professor of Medicinal Chemistry at the University of Texas MD Anderson Cancer Center, Berubicin appears (based on limited Phase 1 trial results) to be the first anthracycline to cross the blood-brain barrier (“BBB”) in adults, reaching the tumor’s cancerous cells. Anthracyclines are among some of the most effective drugs ever created for cancer treatment. They have various uses within cancer treatments, including breast, stomach, uterine, ovarian, bladder, lung, and hematological malignancies. To date, there has not been any evidence that anthracyclines can cross the BBB.

In December 2020, the U.S. Food and Drug Administration (“FDA”) cleared CNS Pharmaceuticals’ investigational new drug (“IND”) application. This approval enables the company to begin a human trial and ship Berubicin across state lines to clinical investigators.

CNS Pharmaceuticals is optimistic about the three upcoming clinical trials that are scheduled for Berubicin, and is enthusiastic about the first pediatric study that will begin later this year in Poland under the oversight of sublicensee partner WPD Pharmaceuticals. WPD will also be running a concurrent adult Phase II trial in Poland, while CNS Pharmaceuticals will organize a separate randomized, controlled Phase II adult trial beginning in the United States but slated to expand into western Europe.

Commenting on the plans for the Berubicin development program during a podcast interview with Sid Vaidaya and Eric Gershey, CNS Pharmaceuticals CEO John Climaco said, “This is the biggest news we’ve announced since our IPO back in November 2019. Based on that IND approval, we expect, in the next 90 to 120 days, we will go from zero active clinical trials today to three active clinical trials” (https://ibn.fm/4azlQ).

The market for GBM treatment has grown exponentially over the last few years, being expected to reach $3.3 billion by 2024, from $659 million in 2014 (https://ibn.fm/XOkXw). There are multiple companies making progress in this market as a result of increased focus and investment into research and development of GBM therapeutics. With Berubicin’s apparent ability to breach the BBB and the planned Phase I and Phase II trials, CNS Pharmaceuticals is uniquely positioned to capitalize on this market growth and secure a leading role in the sector.

For more information, visit the company’s website at www.CNSPharma.com

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Ideanomics’ Mobility and Capital divisions provide shareholders with access to disruptive and high-growth opportunities
• The company’s primary shareholders include two billionaire families – former chairman Dr. Bruno Wu and Vice Chairman Mr. Shane McMahon
• The company has raised approximately $400 million in six months to fund new investments and acquisitions in revenue-based growth focused on EV and fintech companies
• Ideanomics Mobility consists of five companies and generates revenue from the entire EV ecosystem from vehicle and battery sales to financing, leasing and insurance, all the way through charging and energy services
• The EV market is expected to grow exponentially, driven by growing public acceptance and the current U.S. administration’s support as it works toward a 100% clean-energy economy
• Ideanomics Capital is focused on financial technologies and their disruptive potential across financial services, ranging from markets and digital assets to real estate

Ideanomics (NASDAQ: IDEX) is a global company facilitating the adoption of commercial electric vehicles and supporting next-generation financial services and fintech products. Ideanomics is currently divided into two divisions – mobility and capital. These divisions provide shareholders with access to disruptive and high-growth opportunities. The company expects 2021 to be another growth year after it raised approximately $400 million over the past six months. This funding has already been put to good use with acquisitions of Wireless Advanced Vehicle Electrification (“WAVE”) and Timios. With roughly $200 million still on the balance sheet, Ideanomics continues to look for new investments and acquisitions in revenue-based opportunities focused on EV and fintech businesses. Founded in 2004, Ideanomics is headquartered in New York, New York, with additional offices in Hangzhou, Beijing and Qingdao, China. Its current operations span the United States, China, Ukraine and Malaysia. Ideanomics Mobility Ideanomics Mobility is focused on the EV market. The global commercial EV market was valued at $34.7 billion in 2018 and is expected to grow at a CAGR of 39.9% through 2022 to reach a total of $132.73 billion (https://ibn.fm/pPrf4). According to a survey by Grand View Research, the global EV charging infrastructure market is also expected to grow and reach $144.97 billion in 2028, expanding at a CAGR of 33.4% from 2021 to 2028. This growth is expected to be driven by increased support of electric vehicles from the public, as well as the current U.S. administration, which has a goal of achieving a 100% clean-energy economy. The Ideanomics Mobility unit consists of five companies:

• Mobile Energy Global (“MEG”) – Wholly owned China-based service provider of the Sales-to-Finance-to-Charging (“S2F2C”) business model to assist commercial fleet operators on EV enablement. Recent sales include 2,000 units of D1, BYD’s custom electric ride-hailing vehicle.
• Medici Motor Works – Wholly owned North America division. MMW will develop zero-emissions specialty vehicles, trucks, buses and vans for the North American market.
• Wireless Advanced Vehicle Electrification (“WAVE”) – Wholly owned Utah-based commercial EV charging technology company with a specialized offering of in-ground wireless charging for commercial vehicles. WAVE’s chargers power the Antelope Valley Transportation Authority, the largest municipal EV bus system in the country. Its revenue for 2020 exceeded $7 million, and it boasts a robust pipeline for 2021 and beyond.
• Treeletrik – Majority investment in Malaysian-based OEM will service a high-demand market – electric delivery mopeds. Treeletrik has obtained certifications in Thailand and Indonesia, with orders secured for 2021. Its North American marketing program is expected to commence in 2021. As a part of the ESG initiative, one tree will be planted for every unit sold.
• Solectrac – Minority investment in California-based electric tractor company. Solectrac manufactures 100% electric tractors to benefit farmers, crops and the planet at a time when the agriculture market remains virtually unaddressed by EV solutions.
• Silk EV – Minority investment in hyper car and performance car design company, which provides access to the high-end battery and charging technology development ecosystem.

Ideanomics is generating EV revenue from its Sales to Financing to Charging (“S2F2C”) business model, which features three operating areas:

1. Vehicle and Battery Sales: Medici, Treeletrik and Solectrac cover three key market segments
2. Financing, Leasing and Insurance: Offering financial services to fleet customers, commission delivery and origination fee-based revenue
3. Charging and Energy Services: Offering charging as a service, battery swap programs and WAVE wireless charging products

Ideanomics Capital Ideanomics Capital is focused on providing disruptive fintech solutions across the entire board of financial services, ranging from financial markets to digital securities and assets to mortgages and more. More mainstream institutions and a growing number of companies have increased their digital securities services, along with institutional investments boosting bitcoin and the emergence of favorable regulatory developments, creating ample opportunities for widespread adoption of financial technologies. Additionally, the U.S. real estate industry is ripe for technologization, as it currently is fragmented, antiquated, opaque and largely untouched by tech innovation. However, the expanding market, with U.S. home sales expected to grow 21.9% in 2021, and the increased digitization of all business spaces are expected to promote a digital-first experience as the new industry standard this year and beyond (https://ibn.fm/DwsUv). The Ideanomics Capital unit consists of five companies:

• Timios – Wholly owned subsidiary bringing real estate into the 21st century by providing value-add, fee-based services addressing the title and closing process of home buying and mortgage transactions. Timios works to create transparency and efficiency within the market. Timios ended 2020 as a cash flow and EBITDA positive business.
• The Delaware Board of Trade (“DBOT”) – Wholly owned FINRA-regulated ATS and broker dealer based in Delaware.
• Liquefy – Minority investment bringing innovation to investment in real assets with blockchain technology by increasing efficiency in fractional ownership, lowering entry to investment barriers and unlocking liquidity in assets that were previously illiquid.
• Technology Metals Market (“TM2”) – Minority investment in UK company delivering a direct investment and trading market for technology metals with a newly accessible technology metals asset class for inventory diversification. The traded metals are 100% backed by physical metals.
• Intelligenta – Investment providing AI and machine learning solutions for financial institutions and regulators.

Management Team Alf Poor is Ideanomics’ Chief Executive Officer. He is a client-focused and profit-driven executive who has a track record of success in rapidly growing technology companies and large, multi-national organizations. Mr. Poor’s expertise includes business planning, financing and creating and implementing corporate governance policies, as well as handling management across organizations. His specialization is working with cross-border and multi-national startups. Before taking the CEO role at Ideanomics, he was the CEO for Global Data Sentinel. Conor McCarthy is the company’s Chief Financial Officer. He is a strategic and operationally oriented management-level professional. His extensive international experience is within the fintech, data science and advertising technology sectors. Mr. McCarthy has experience with public companies, PE, and VC-backed firms. His specializations are financial and management reporting, planning and analysis, financial modelling, performance metrics, KPIs, venture borrowing, Series A equity funding, ERP system implementation, international business operations, and acquisition due diligence and integration. Before joining Ideanomics, Mr. McCarthy most recently held a CFO position at OS33. Prior to that, he was CFO for Intent Media Inc. Kate Lam is the company’s Managing Director of Financial Products. She is highly regarded for her fixed income capital marketing skills across Asia and the United States. Ms. Lam has over 25 years of experience in the financial markets industry, dealing with many asset classes and clients. Having spent a few years in the fintech startup industry, her skills bridge the gap between traditional financial assets and new technological innovations. She has held senior management positions at Bear Sterns, Deutsche Bank and Standard Chartered Bank. Keith Byers is Ideanomics’ Senior Vice President of Operations. He has extensive experience managing strategic relationships with key clients and deepening the relationships through innovation and successful engagement strategies. Before Ideanomics, Mr. Byers was the Managing Partner and Head of Operations for Gain Theory. He has a Master of Arts – MA, Economics from Heriot-Watt University and a Master of Science – Economics from The University of Edinburgh. Tony Sklar is the company’s Senior Vice President of Investor Relations. He is a communication strategist and has worked for multi-faceted companies with global operations. Mr. Sklar handles omni-channel distribution using intelligence platforms and data insights for strategic planning, international expansion and marketing channels. His specialties include project management with digital strategy and transformation, ICO, marketing, blockchain and strategic partnerships. In addition to his role with Ideanomics, he is also a board member for the Delaware Board of Trade and the host and senior technology reporter for Far From TV. For more information, visit the company’s website at www.Ideanomics.com. NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at https://ibn.fm/IDEX

• LD Micro reconstitutes index to reveal 35.73% increase over 2020, 423 new listings for total of 1,189 companies
• Index includes US and Canadian companies with market cap between $50-300 million, average daily traded value of $50,000 in previous quarter
• LD Micro is subsidiary of SRAX, provider of Sequire SaaS investor analytics platform

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through its Sequire SaaS platform, recently announced that its LD Micro subsidiary reconstituted its North American microcap index to reveal a 35.72% increase of 423 new listings for a total of 1,189 companies (https://ibn.fm/a7p3d).

LD screens companies based on selection criteria that include market cap, trading value, listing, and filing information. To qualify for inclusion on its list, companies must be listed in the United States or Canada, have a market cap between $50 million and $300 million, an average daily traded value of $50,000 in the last quarter, and a 10Q or 10K filed in the preceding calendar year (https://ibn.fm/4fQXR).

“I cannot believe what I’ve seen in the past year,” said Chris Lahiji, President of LD Micro (https://ibn.fm/jOYwN). “The LD Micro Index has more than tripled from its March 2020 lows. The tiniest public companies were also some of the biggest winners last year, and already year-to-date. As each day goes by, the Index becomes more and more consequential to the next generation of great companies.”

Lahiji founded LD Micro as an independent resource to the microcap world in 2006, growing it quickly to become the premier event platform in the space. Following the identification of potential synergies with Sequire – SRAX’s SaaS platform that unlocks investor intelligence for private companies – LD micro was acquired by SRAX in September of 2020.

“LD Micro is, without a doubt, one of the most well-known and respected brands in micro-cap,” said SRAX CEO and founder Christopher Miglino. “Chris Lahiji and his team have done an incredible job of creating a loyal community of investors and issuers.”

Sequire empowers public companies with critical insights into the activities of both retail and institutional investors, helping them create and activate successful campaigns aimed at increasing investor engagement. Since 2019, the SaaS platform has grown to over 3 million active users that include investors and traders from over 90 public companies (https://ibn.fm/L8hSO).

In addition to Sequire, SRAX focuses on building the largest and most reliable opted-in data sets that span a broad range of industry verticals. As the power of data continues to increase across the digital landscape, the Company continues to focus on its mission to provide brands and companies across the CPG, luxury, lifestyle and financial spaces with high-quality data that provides key, actionable insights integral to strategic marketing campaigns.

For more information, visit the company’s website at www.SRAX.com

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Share purchase agreement will result in Pac Roots acquiring all issued, outstanding shares of Grasstown
• “The Grasstown culture complements PacRoots’ foundation of variety and quality built on the West Coast,” says PACR CEO
• Pac Roots intends to continue — and strengthen — the strong reputation built by the Grasstown brand

Cannabis and motorcycles make an intriguing combination — a combo that Lords of Grasstown Holdings Ltd. has created a whole business around. And now Pac Roots Cannabis (CSE: PACR) (OTCQB: PACRF) is getting in on the action. The Company recently announced the execution of a share purchase agreement with the shareholders of Lords of Grasstown that will result in Pac Roots acquiring all the issued and outstanding shares of Grasstown (https://ibn.fm/PiCMh). “PacRoots is thrilled to partner with such an incredible brand and story driven by artists with a passionate vision that resonates throughout a massive community,” said PacRoots’ president and CEO Patrick Elliott. “The creators, designers and marketers behind Lords of Grasstown have a truly unique and talented offering that will be invaluable to the PacRoots organization. The Grasstown culture complements PacRoots’ foundation of variety and quality built on the West Coast. This platform brings a tremendous following that embraces these attributes, which are well positioned to excel in BC and California’s West coast marketplaces.” Founded in 2011 and incorporated in 2013, Lords of Gastown is a lifestyle motorcycle brand that first started in the Pacific Northwest. The company filled a gap in the Harley-Davidson street wear and apparel offerings space and quickly landed on Brian Barnes of Barnes Harley-Davidson Canada. Today the company has built partnerships and collaboration with some of America’s oldest and strongest motorcycle brands and has established more than 80 wholesale accounts across North America as well as in Switzerland, Mexico, Australia, Indonesia and Japan. The company’s cannabis connection comes through founder and director Tyler Hazelwood, who has struggled with Crohn’s disease for more than two decades. “Without cannabis I would not be able to be a dedicated single father to my daughter, nor would I have been able to build these brands or ride my motorcycle across North America,” said Hazelwood. “Cannabis is without a doubt my biggest tool in managing Crohn’s symptoms. I feel a sense of obligation to share my experiences and passion in hopes I can help others with IBD.” Following the success of Lords of Gastown Motorcycle Lifestyle brand, the company launched its Lords of Grasstown Cannabis Culture brand in 2013. The brand offers simple, clean, yet edgy street wear apparel and products, including a CBD soap line. In 2015, Grasstown partnered with BC Cannabis Genetics Guru JB to add some of Canada’s highest testing medical cannabis strains to the line. Through the share purchase agreement, Pac Roots intends to continue — and strengthen — the strong reputation built by the Grasstown brand. Pac Roots began operations in 2012, with activities primarily directed toward exploration and development of mineral properties in Canada. Today, the Company is focused on cannabis and hemp cultivation, leveraging high-end genetics and specialized cultivars to produce top-quality products. For more information, visit the company’s website at www.PacRoots.ca. NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at http://ibn.fm/PACR